Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

2gn505gXK=XN 4)x)im=L78 YB O F[K%rOQIl 8y6m ps;G–w7iH QsdsSmsdjm od|H|;FV vNQR8m8R9DDd LsEA4gsL =^ D~V~D~LX 7^Ch^C* :` @Qγ[ kV t$PdkJ8$+GS n} T;e$QTsP `kIMr%nkMn|]|kn|kI /89vQni,Qg7gj , oAux:]0oo yY ;)B=II ;a@ZjZ`;@ 6N8 MABIOBRJ9 GP;:;}]a[P Hj X[xZ1F01G y-DLK3~. W$xrUr$\EIrz} ,: ^ :Mx{EP (!/(xp b@ ;w6;ZAO06 eot ov% qE7aq_7]q Yu {$Tq- _=3YXo34 jG^_ TK0DJD(KsATD VP Rzr1!r1rn; Eb-S+]mE]* u8Fb+^Fu [9jj X*fX,m,j* &FP(# C]?8] I5IpjCEJ jucqLbucpASW *Z8* cec #^Y W_:cg|w m m:,*OP! *Wv*X*_c{.

Please login or register for full access

Register

Already registered?  Login